Preferred Label : Imaradenant;
NCIt synonyms : A2AR Antagonist AZD4635; Adenosine A2A Receptor Antagonist AZD4635;
NCIt definition : An orally bioavailable antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with
potential immunomodulating and antineoplastic activities. Upon administration, imaradenant
selectively binds to and inhibits A2AR expressed on T-lymphocytes. This blocks tumor-released
adenosine from interacting with A2AR and prevents the adenosine/A2AR-mediated inhibition
of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes,
and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled
receptor, is highly expressed on the cell surfaces of T-cells and, upon activation
by adenosine, inhibits T-cell proliferation and activation. Adenosine is often overproduced
by cancer cells and plays a key role in immunosuppression.;
UNII : 770140J08A;
InChIKey : NCWQLHHDGDXIJN-UHFFFAOYSA-N;
CAS number : 1321514-06-0;
Molecule name : AZD-4635; HTL-1071;
NCI Metathesaurus CUI : CL545814;
Origin ID : C148039;
UMLS CUI : C5418239;
Semantic type(s)
- concept_is_in_subset
- has_target
